Table 3

Seroprevalence at phase II by SARS-CoV-2 infection and vaccination status

	Positive		Negative		Total	Estimated seroprevalence in general population
	N	%	N	%		%	95% CI	P value
SARS-CoV-2− and no vaccination	728	25.56	2120	74.44	2848	23.97	22.18% to 25.85%
SARS-CoV-2+ and no vaccination	4367	91.00	432	9.00	4799	89.57	88.33% to 90.70%
SARS-CoV-2− and with vaccination	7285	97.20	210	2.80	7495	97.36	96.72% to 97.88%	<0.001
SARS-CoV-2+ and with vaccination	6969	99.73	19	0.27	6988	99.81	99.68% to 99.89%
Total	19 349	87.43	2781	12.57	22 130	84.37	83.64% to 85.07%

SARS-CoV-2−=seronegative at phase I AND self-report of negative or not done PCR test between phase I and II.
SARS-CoV-2+=seropositive at phase I OR self-report of positive PCR test between phase I and II.